Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI)

    Predicts overall and progression-free survival in DLBCL based on risk factors.
    Favorite

    INSTRUCTIONS

    Note: IPI results are included for historical comparisons only. Use in CD20+ DLBCL patients. Do not use in patients with HIV, secondary malignancies, low grade lymphoproliferative disorders, or comorbidities precluding curative therapy attempt.

    When to Use
    Pearls/Pitfalls
    Why Use

    Use in CD20+ DLBCL patients. Do not use in patients with HIV, secondary malignancies, low grade lymphoproliferative disorders, or comorbidities precluding curative therapy attempt.

    • The International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI) estimates 4-year progression-free survival and 4-year overall survival for patients with diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL).
    • The R-IPI provides greater discrimination amongst DLBCL patients with differing survival based on easily obtained factors.
    • Does not identify any risk group with 4-year survival <50%; hence, other molecular or genetic markers are being researched to help select the worst-outcome patients for alternative treatment/clinical trials.

    Using the same criteria as the older International Prognostic Index (IPI), the revised IPI (R-IPI) discriminates among three different prognostic groups (versus two by IPI), providing more clinical relevance.

    ≤60 years
    0
    >60 years
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights

    Management

    Patients with poor prognosis should be strongly considered for clinical trial enrollment and tertiary center referral for investigational therapy.

    Critical Actions

    Correct staging and selecting correct performance status are the most potentially difficult factors.

    Content Contributors
    About the Creator
    Dr. Laurie H. Sehn
    Are you Dr. Laurie H. Sehn?
    Content Contributors